Chemotherapy for good-risk germ-cell tumors

Seminars in Urologic Oncology

Volumn 20, Issue 4, 2002, Pages 244-250

  Ryan, Charles J ^a   Bajorin, Dean F ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; Germ cell tumors

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; VINBLASTINE;

BONE MARROW SUPPRESSION; CANCER RISK; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; GERM CELL TUMOR; HUMAN; LUNG TOXICITY; MALE; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REVIEW; RISK BENEFIT ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CARBOPLATIN; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; GERMINOMA; HUMANS; MALE; RISK FACTORS; TESTICULAR NEOPLASMS;

EID: 0036863924     PISSN: 10810943     EISSN: None     Source Type: Journal    
DOI: 10.1053/suro.2002.37208     Document Type: Review

References (22)

1. Bosl GJ, et al: VAB 6: An effective chemotherapy regimen for patients with germ cell tumors. J Clin Oncol 4:1493-2499, 1986
2. Einhorn LH, et al: Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: A Southeastern Cancer Study Group protocol. J Clin Oncol 7:387-391, 1989
3. Bajorin DF, et al: Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: A multi-institutional study. J Clin Oncol 11:598-606, 1993
4. Einhorn LH, Williams SD: Chemotherapy of disseminated testicular cancer: A random prospective study. Cancer 46:1339-1344, 1980
5. Williams SD, Einhorn LH: Etoposide salvage therapy for refractory germ cell tumors: An update. Cancer Treat Rev 9:67-71, 1982
6. Williams SD, et al: Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 317:1433-1438, 1987
7. Fitzharris B, et al: VP16-213 as a single agent in advanced testicular tumors. Eur J Cancer 16:1193-1197, 1980
8. Peckham MJ, et al: The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP). Br J Cancer 47:613-619, 1983
9. Bajorin D, et al: Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies J Clin Oncol 6:786-792, 1988
10. IGCCCG, International Germ Cell Consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers J Clin Oncol 15:594-603, 1997
11. Fleming I, et al: AJCC Cancer Staging Manual (Ed 5). Philadelphia, Lippincott-Raven, 1997
12. Samson MK, et al: Dose response and dose-survival advantage for high- versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. Cancer 53:1029-1035, 1984
13. Horwich A, et al: Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A multi-institutional medical research council/European Organization for Research and Treatment of Cancer trial. J Clin Oncol 15:1844-1852, 1997
14. Bajorin D, Bosl G: Bleomycin in germ cell tumor therapy: Not all regimens are created equal. J Clin Oncol 1717-1719, 1997
15. de Wit RJ, Wilkinson PM, de Mulder PH, et al: Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 19:1629-1640, 2001
16. Williams SD, et al: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435-1440, 1987
17. Vogelzang NJ, Torkenson JL, Kennedy BJ: Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer 56:2765-2770, 1985
18. Loehrer PJ, et al: Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: An Eastern Cooperative Oncology Group Trial. J Clin Oncol 13:470-476, 1995
19. Levi JA, et al: The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. J Clin Oncol 11:1300-1305, 1993
20. Bosl GJ. et al: A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors J Clin Oncol 6:1231-1238, 1988
21. de Wit R, et al: Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cooperative Group. J Clin Oncol 15:1837-1843, 1997
22. Culine S, et al: Are 3 cycles of bleomycin, etoposide and cisplatin (3BEP) or 4 cycles of etoposide and cisplatin (4EP) equivalent regimens for patients (pts) with good-risk metastatic non seminomatous germ cell tumors (NSGCT)? Prelimmary results of a randomized trial. Proc ASCO 18:309, 1999